Clinical trial
PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of…
NCT00362544 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00362544 |
|---|---|
| Title | PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia |
| Official title | Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | Ambisome |
| Enrollment | 30 |
| Start date | Oct 1, 2003 |
| Completion | Mar 1, 2006 |
| First posted | Aug 10, 2006 |
| Last update posted | Jul 9, 2015 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: